On the public citation graph

Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

0 signed · 917 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archsurg.1995.01430110075014openalex-snapshot

Preemptive Ganciclovir Therapy in Cytomegalovirus-Seropositive Renal Transplants Recipients

inferredcites →https://doi.org/10.1002/14651858.cd005129.pub2openalex-snapshot

Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients

inferredcites →https://doi.org/10.1002/rmv.514openalex-snapshot

The case for cytomegalovirus prophylaxis in solid organ transplantation

inferredcites →https://doi.org/10.1002/rmv.655openalex-snapshot

Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection

inferredcites →https://doi.org/10.1007/s40265-018-0943-1openalex-snapshot

New Developments in the Management of Cytomegalovirus Infection After Transplantation

inferredcites →https://doi.org/10.1016/j.antiviral.2011.03.184openalex-snapshot

Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation

inferredcites →https://doi.org/10.1016/j.antiviral.2014.10.016openalex-snapshot

Everolimus-based immunosuppressive regimens in lung transplant recipients: Impact on CMV infection

inferredcites →https://doi.org/10.1016/j.antiviral.2016.12.003openalex-snapshot

Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene

inferredcites →https://doi.org/10.1016/j.bbmt.2018.03.028openalex-snapshot

Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution

inferredcites →https://doi.org/10.1016/j.bbmt.2018.09.038openalex-snapshot

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

inferredcites →https://doi.org/10.1016/j.cmi.2018.05.010openalex-snapshot

Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment

inferredcites →https://doi.org/10.1016/j.eimc.2009.07.008openalex-snapshot

Direct and indirect effects of cytomegalovirus: can we prevent them?

inferredcites →https://doi.org/10.1016/j.healun.2004.03.009openalex-snapshot

Cardiac allograft vasculopathy after heart transplantation: risk factors and management

inferredcites →https://doi.org/10.1016/j.healun.2011.02.017openalex-snapshot

Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial

inferredcites →https://doi.org/10.1016/j.jcv.2011.12.019openalex-snapshot

Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis

inferredcites →https://doi.org/10.1016/j.jcv.2016.06.013openalex-snapshot

Immune-based guidance of foscarnet treatment duration in a transplant recipient with ganciclovir-resistant cytomegalovirus infection

inferredcites →https://doi.org/10.1016/j.jcv.2018.04.013openalex-snapshot

Cytomegalovirus sequence variability, amplicon length, and DNase-sensitive non-encapsidated genomes are obstacles to standardization and commutability of plasma viral load results

inferredcites →https://doi.org/10.1016/j.jcv.2018.06.009openalex-snapshot

T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients

inferredcites →https://doi.org/10.1016/j.mayocp.2018.09.017openalex-snapshot

Application of a New Paradigm for Cytomegalovirus Disease Prevention in Mayo Clinic’s First Face Transplant

inferredcites →https://doi.org/10.1016/j.transproceed.2015.09.070openalex-snapshot

Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation

inferredcites →https://doi.org/10.1016/s0002-9343(97)80021-6openalex-snapshot

The Independent Role of Cytomegalovirus as a Risk Factor for Invasive Fungal Disease in Orthotopic Liver Transplant Recipients

inferredcites →https://doi.org/10.1016/s0041-1345(01)02101-7openalex-snapshot

Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study

inferredcites →https://doi.org/10.1016/s0140-6736(00)02350-3openalex-snapshot

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

inferredcites →https://doi.org/10.1016/s0140-6736(00)02607-6openalex-snapshot

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants

inferredcites →https://doi.org/10.1016/s0140-6736(11)60136-0openalex-snapshot

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

inferredcites →https://doi.org/10.1016/s0140-6736(97)05535-9openalex-snapshot

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients

inferredcites →https://doi.org/10.1016/s1053-2498(02)00435-7openalex-snapshot

Controversies in lung transplantation: management of cytomegalovirus infections

inferredcites →https://doi.org/10.1016/s1053-2498(02)00463-1openalex-snapshot

Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients

inferredcites →https://doi.org/10.1034/j.1399-3062.2002.t01-1-02008.xopenalex-snapshot

Clinical characteristics of 13 solid organ transplant recipients with ganciclovir‐resistant cytomegalovirus infection

inferredcites →https://doi.org/10.1038/cti.2015.5openalex-snapshot

Adoptive T‐cell immunotherapy for ganciclovir‐resistant CMV disease after lung transplantation

inferredcites →https://doi.org/10.1038/leu.2017.16openalex-snapshot

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

inferredcites →https://doi.org/10.1056/nejm199905133401903openalex-snapshot

Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation

inferredcites →https://doi.org/10.1056/nejmoa1303688openalex-snapshot

CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation

inferredcites →https://doi.org/10.1056/nejmoa1706640openalex-snapshot

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

inferredcites →https://doi.org/10.1080/17512433.2018.1501557openalex-snapshot

Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation

inferredcites →https://doi.org/10.1084/jem.190.2.177openalex-snapshot

The Dynamics of Human Cytomegalovirus Replication in Vivo

inferredcites →https://doi.org/10.1086/315242openalex-snapshot

Cytomegalovirus (CMV) DNA Load Predicts Relapsing CMV Infection after Solid Organ Transplantation

inferredcites →https://doi.org/10.1086/324516openalex-snapshot

Allograft Rejection Predicts the Occurrence of Late‐Onset Cytomegalovirus (CMV) Disease among CMV‐Mismatched Solid Organ Transplant Patients Receiving Prophylaxis with Oral Ganciclovir

inferredcites →https://doi.org/10.1086/338143openalex-snapshot

High Incidence of Ganciclovir‐Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy

inferredcites →https://doi.org/10.1086/339449openalex-snapshot

Preemptive Use of Oral Ganciclovir to Prevent Cytomegalovirus Infection in Liver Transplant Patients: A Randomized, Placebo‐Controlled Trial

inferredcites →https://doi.org/10.1086/340101openalex-snapshot

Combination Antiviral Therapy for Ganciclovir‐Resistant Cytomegalovirus Infection in Solid‐Organ Transplant Recipients

inferredcites →https://doi.org/10.1086/340653openalex-snapshot

Human Cytomegalovirus (HCMV) Replication Dynamics in HCMV‐Naive and ‐Experienced Immunocompromised Hosts

inferredcites →https://doi.org/10.1086/342601openalex-snapshot

Cytomegalovirus (CMV) Virus Load Kinetics to Predict Recurrent Disease in Solid‐Organ Transplant Patients with CMV Disease

inferredcites →https://doi.org/10.1086/375194openalex-snapshot

Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir

inferredcites →https://doi.org/10.1086/375743openalex-snapshot

Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus

inferredcites →https://doi.org/10.1086/382753openalex-snapshot

Absence of Cytomegalovirus‐Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solid‐Organ Transplant Recipients

inferredcites →https://doi.org/10.1086/425002openalex-snapshot

The Clinical Impact of Ganciclovir Prophylaxis on the Occurrence of Bacteremia in Orthotopic Liver Transplant Recipients

inferredcites →https://doi.org/10.1086/425905openalex-snapshot

Kinetics of Cytomegalovirus Load Decrease in Solid‐Organ Transplant Recipients after Preemptive Therapy with Valganciclovir

inferredcites →https://doi.org/10.1086/528718openalex-snapshot

Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney Transplantation

inferredcites →https://doi.org/10.1086/598952openalex-snapshot

An Assessment of Donor‐to‐Recipient Transmission Patterns of Human Cytomegalovirus by Analysis of Viral Genomic Variants

inferredcites →https://doi.org/10.1086/652438openalex-snapshot

Cytomegalovirus Seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988–2004

inferredcites →https://doi.org/10.1093/cid/ciq143openalex-snapshot

Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysis

inferredcites →https://doi.org/10.1093/cid/cis900openalex-snapshot

An International Multicenter Performance Analysis of Cytomegalovirus Load Tests

inferredcites →https://doi.org/10.1093/cid/cis993openalex-snapshot

Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study

inferredcites →https://doi.org/10.1093/cid/cit096openalex-snapshot

Virologic Suppression Measured by a Cytomegalovirus (CMV) DNA Test Calibrated to the World Health Organization International Standard Is Predictive of CMV Disease Resolution in Transplant Recipients

inferredcites →https://doi.org/10.1093/cid/cit521openalex-snapshot

Detection of Cytomegalovirus DNA in Plasma as an Adjunct Diagnostic for Gastrointestinal Tract Disease in Kidney and Liver Transplant Recipients

inferredcites →https://doi.org/10.1093/cid/ciu589openalex-snapshot

Preformed Frequencies of Cytomegalovirus (CMV)–Specific Memory T and B Cells Identify Protected CMV-Sensitized Individuals Among Seronegative Kidney Transplant Recipients

inferredcites →https://doi.org/10.1093/cid/ciw370openalex-snapshot

Are We There Yet? Impact of the First International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples

inferredcites →https://doi.org/10.1093/cid/ciw668openalex-snapshot

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

inferredcites →https://doi.org/10.1093/cid/cix696openalex-snapshot

Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1093/cid/cix793openalex-snapshot

Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis

inferredcites →https://doi.org/10.1093/cid/ciy295openalex-snapshot

Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1093/cid/ciy549openalex-snapshot

Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial

inferredcites →https://doi.org/10.1093/cid/ciy696openalex-snapshot

Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials

inferredcites →https://doi.org/10.1093/cid/ciy706openalex-snapshot

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

inferredcites →https://doi.org/10.1093/clinids/20.5.1346openalex-snapshot

Pretransplantation Assessment of the Risk of Lymphoproliferative Disorder

inferredcites →https://doi.org/10.1093/infdis/171.4.1014openalex-snapshot

OKT3 Treatment for Allograft Rejection Is a Risk Factor for Cytomegalovirus Disease in Liver Transplantation

inferredcites →https://doi.org/10.1093/infdis/jix069openalex-snapshot

Determination of the Biological Form of Human Cytomegalovirus DNA in the Plasma of Solid-Organ Transplant Recipients

inferredcites →https://doi.org/10.1093/infdis/jiy309openalex-snapshot

Assigning Cytomegalovirus Status in Children Awaiting Organ Transplant: Viral Shedding, CMV-Specific T Cells, and CD27−CD28−CD4+ T Cells

inferredcites →https://doi.org/10.1093/ofid/ofx143openalex-snapshot

Comparison of Standardized Cytomegalovirus (CMV) Viral Load Thresholds in Whole Blood and Plasma of Solid Organ and Hematopoietic Stem Cell Transplant Recipients with CMV Infection and Disease

inferredcites →https://doi.org/10.1093/ofid/ofy229.2195openalex-snapshot

LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+R−) Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial

inferredcites →https://doi.org/10.1093/ofid/ofy230openalex-snapshot

Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation

inferredcites →https://doi.org/10.1097/00007890-199911150-00015openalex-snapshot

CLINICAL UTILITY OF QUANTITATIVE CYTOMEGALOVIRUS VIRAL LOAD DETERMINATION FOR PREDICTING CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1

inferredcites →https://doi.org/10.1097/00007890-200105150-00018openalex-snapshot

LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1

inferredcites →https://doi.org/10.1097/00007890-200203270-00025openalex-snapshot

The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease

inferredcites →https://doi.org/10.1097/00041552-199611000-00009openalex-snapshot

Mycophenolate mofetil in kidney transplantation

inferredcites →https://doi.org/10.1097/mot.0000000000000541openalex-snapshot

Drug-resistant cytomegalovirus: clinical implications of specific mutations

inferredcites →https://doi.org/10.1097/qco.0b013e328259c33bopenalex-snapshot

Cytomegalovirus-associated allograft rejection in heart transplant patients

inferredcites →https://doi.org/10.1097/qco.0b013e32834cfb58openalex-snapshot

The biology of cytomegalovirus drug resistance

inferredcites →https://doi.org/10.1097/tp.0000000000000386openalex-snapshot

The Role of Secondary Cytomegalovirus Prophylaxis for Kidney and Liver Transplant Recipients

inferredcites →https://doi.org/10.1097/tp.0000000000000832openalex-snapshot

Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation

inferredcites →https://doi.org/10.1097/tp.0000000000001418openalex-snapshot

Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection

inferredcites →https://doi.org/10.1097/tp.0000000000002191openalex-snapshot

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

inferredcites →https://doi.org/10.1097/tp.0000000000002373openalex-snapshot

Deep Profiling of the CD8+ T-cell Compartment Identifies Activated Cell Subsets and Multifunctional Responses Associated With Control of Cytomegalovirus Viremia

inferredcites →https://doi.org/10.1097/tp.0000000000002396openalex-snapshot

Clinical Correlation of Cytomegalovirus Infection With CMV-specific CD8+ T-cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1097/tp.0b013e3181bc0301openalex-snapshot

Preemptive Versus Sequential Prophylactic-Preemptive Treatment Regimens for Cytomegalovirus in Renal Transplantation: Comparison of Treatment Failure and Antiviral Resistance

inferredcites →https://doi.org/10.1097/tp.0b013e3181e94106openalex-snapshot

Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes

inferredcites →https://doi.org/10.1097/tp.0b013e3181ff1493openalex-snapshot

Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study

inferredcites →https://doi.org/10.1097/tp.0b013e3181ff8719openalex-snapshot

The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response

inferredcites →https://doi.org/10.1097/tp.0b013e318200b9f0openalex-snapshot

Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients

inferredcites →https://doi.org/10.1097/tp.0b013e31821fad25openalex-snapshot

Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant Recipients

inferredcites →https://doi.org/10.1097/tp.0b013e31822fa4b7openalex-snapshot

Clinical Utility of Molecular Surveillance for Cytomegalovirus After Antiviral Prophylaxis in High-Risk Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1097/tp.0b013e318238dab3openalex-snapshot

Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial

inferredcites →https://doi.org/10.1097/tp.0b013e31823c1cd4openalex-snapshot

Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia

inferredcites →https://doi.org/10.1097/tp.0b013e318276a1efopenalex-snapshot

Everolimus-Treated Renal Transplant Recipients Have a More Robust CMV-Specific CD8+ T-Cell Response Compared With Cyclosporine- or Mycophenolate-Treated Patients

inferredcites →https://doi.org/10.1111/ajt.12013openalex-snapshot

Infections Following Facial Composite Tissue Allotransplantation—Single Center Experience and Review of the Literature

inferredcites →https://doi.org/10.1111/ajt.13023openalex-snapshot

Adoptive T Cell Immunotherapy for Treatment of Ganciclovir-Resistant Cytomegalovirus Disease in a Renal Transplant Recipient

inferredcites →https://doi.org/10.1111/ajt.14347openalex-snapshot

An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation

inferredcites →https://doi.org/10.1111/ajt.14925openalex-snapshot

A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor

inferredcites →https://doi.org/10.1111/ajt.15135openalex-snapshot

Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection

inferredcites →https://doi.org/10.1111/ctr.12156openalex-snapshot

Induction therapy and m TOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients

inferredcites →https://doi.org/10.1111/ctr.12671openalex-snapshot

Treatment of cytomegalovirus infection and disease pre‐ and post‐quantitative nucleic acid test standardization: does use of a more sensitive assay lead to longer treatment duration?

inferredcites →https://doi.org/10.1111/ctr.12686openalex-snapshot

Cytomegalovirus disease is associated with higher all‐cause mortality after lung transplantation despite extended antiviral prophylaxis

inferredcites →https://doi.org/10.1111/ctr.13149openalex-snapshot

Cytomegalovirus ( CMV ) DNA quantification in bronchoalveolar lavage fluid of immunocompromised patients with CMV pneumonia

inferredcites →https://doi.org/10.1111/j.1399-0012.2007.00750.xopenalex-snapshot

CMV‐hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta‐analysis

inferredcites →https://doi.org/10.1111/j.1399-0012.2007.00761.xopenalex-snapshot

Emergence of drug‐resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes

inferredcites →https://doi.org/10.1111/j.1399-0012.2009.01076.xopenalex-snapshot

The impact of invasive fungal diseases on survival after lung transplantation

inferredcites →https://doi.org/10.1111/j.1399-3062.2010.00550.xopenalex-snapshot

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

inferredcites →https://doi.org/10.1111/j.1399-3062.2012.00723.xopenalex-snapshot

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis

inferredcites →https://doi.org/10.1111/j.1432-2277.2009.01017.xopenalex-snapshot

A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection

inferredcites →https://doi.org/10.1111/j.1432-2277.2011.01285.xopenalex-snapshot

Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients

inferredcites →https://doi.org/10.1111/j.1432-2277.2011.01321.xopenalex-snapshot

The risk of cytomegalovirus recurrence after kidney transplantation

inferredcites →https://doi.org/10.1111/j.1600-6143.2004.00382.xopenalex-snapshot

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2004.00391.xopenalex-snapshot

Clinical Utility of Cytomegalovirus Viral Load Testing for Predicting CMV Disease in D+/R- Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2004.00571.xopenalex-snapshot

Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation

inferredcites →https://doi.org/10.1111/j.1600-6143.2005.00797.xopenalex-snapshot

Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High-risk CMV D+/R- Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2005.00866.xopenalex-snapshot

A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2005.01207.xopenalex-snapshot

American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation

inferredcites →https://doi.org/10.1111/j.1600-6143.2006.01413.xopenalex-snapshot

Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2007.01910.xopenalex-snapshot

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2007.02026.xopenalex-snapshot

A Survey of CMV Prevention Strategies After Liver Transplantation

inferredcites →https://doi.org/10.1111/j.1600-6143.2007.02031.xopenalex-snapshot

Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal Transplantation

inferredcites →https://doi.org/10.1111/j.1600-6143.2007.02133.xopenalex-snapshot

Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial

inferredcites →https://doi.org/10.1111/j.1600-6143.2009.02617.xopenalex-snapshot

Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2009.02618.xopenalex-snapshot

Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2009.02861.xopenalex-snapshot

Clinical Predictors of Relapse after Treatment of Primary Gastrointestinal Cytomegalovirus Disease in Solid Organ Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2010.03074.xopenalex-snapshot

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients

inferredcites →https://doi.org/10.1111/j.1600-6143.2011.03530.xopenalex-snapshot

First Report of Successful Treatment of Multidrug-Resistant Cytomegalovirus Disease with the Novel Anti-CMV Compound AIC246

inferredcites →https://doi.org/10.1111/j.1600-6143.2011.03674.xopenalex-snapshot

Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials

inferredcites →https://doi.org/10.1111/j.1600-6143.2011.03724.xopenalex-snapshot

Late Cytomegalovirus Transmission and Impact of T-Depletion in Clinical Islet Transplantation

inferredcites →https://doi.org/10.1111/j.1600-6143.2012.04087.xopenalex-snapshot

Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy

inferredcites →https://doi.org/10.1111/petr.12786openalex-snapshot

A risk‐stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients

inferredcites →https://doi.org/10.1111/petr.13229openalex-snapshot

Assignment of cytomegalovirus infection status in infants awaiting solid organ transplant: Viral detection methods as adjuncts to serology

inferredcites →https://doi.org/10.1111/tid.12349openalex-snapshot

Increased risk of breakthrough infection among cytomegalovirus donor‐positive/recipient‐negative kidney transplant recipients receiving lower‐dose valganciclovir prophylaxis

inferredcites →https://doi.org/10.1111/tid.12447openalex-snapshot

It's not too late: a proposal to standardize the terminology of “late‐onset” cytomegalovirus infection and disease in solid organ transplant recipients

inferredcites →https://doi.org/10.1111/tid.12507openalex-snapshot

Resistant cytomegalovirus in intestinal and multivisceral transplant recipients

inferredcites →https://doi.org/10.1111/tid.12516openalex-snapshot

Guillain–Barré syndrome associated with resistant cytomegalovirus infection after face transplantation

inferredcites →https://doi.org/10.1111/tid.12531openalex-snapshot

Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients

inferredcites →https://doi.org/10.1111/tid.12537openalex-snapshot

Ganciclovir‐resistant cytomegalovirus infection in solid organ transplant recipients: a single‐center retrospective cohort study

inferredcites →https://doi.org/10.1111/tid.12601openalex-snapshot

Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients

inferredcites →https://doi.org/10.1111/tri.13110openalex-snapshot

Clinical validation of a novel enzyme-linked immunosorbent spot assay-basedin vitrodiagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study

inferredcites →https://doi.org/10.1128/.38.6.2122-2127.2000openalex-snapshot

Comparison of Quantitative Cytomegalovirus (CMV) PCR in Plasma and CMV Antigenemia Assay: Clinical Utility of the Prototype AMPLICOR CMV MONITOR Test in Transplant Recipients

inferredcites →https://doi.org/10.1128/aac.00922-18openalex-snapshot

New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir

inferredcites →https://doi.org/10.1128/aac.01855-18openalex-snapshot

Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety

inferredcites →https://doi.org/10.1128/aac.05559-11openalex-snapshot

Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure

inferredcites →https://doi.org/10.1128/cmr.00009-10openalex-snapshot

Antiviral Drug Resistance of Human Cytomegalovirus

inferredcites →https://doi.org/10.1128/cmr.00015-13openalex-snapshot

Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation

inferredcites →https://doi.org/10.1128/jcm.00391-17openalex-snapshot

Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene

inferredcites →https://doi.org/10.1128/jcm.01605-13openalex-snapshot

Detection of Cytomegalovirus Drug Resistance Mutations by Next-Generation Sequencing

inferredcites →https://doi.org/10.1128/jcm.39.12.4472-4476.2001openalex-snapshot

Comparative Quantitation of Cytomegalovirus (CMV) DNA in Solid Organ Transplant Recipients with CMV Infection by Using Two High-Throughput Automated Systems

inferredcites →https://doi.org/10.1128/jcm.41.7.3167-3174.2003openalex-snapshot

Comparison of LightCycler-Based PCR, COBAS Amplicor CMV Monitor, and pp65 Antigenemia Assays for Quantitative Measurement of Cytomegalovirus Viral Load in Peripheral Blood Specimens from Patients after Solid Organ Transplantation

inferredcites →https://doi.org/10.1182/bloodadvances.2017010223openalex-snapshot

Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells

inferredcites →https://doi.org/10.1200/jco.2017.73.0655openalex-snapshot

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation

inferredcites →https://doi.org/10.1371/journal.pone.0193968openalex-snapshot

Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study

inferredcites →https://doi.org/10.2165/10898540-000000000-00000openalex-snapshot

New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation

inferredcites →https://doi.org/10.2215/cjn.13221216openalex-snapshot

CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor–Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials

inferredcites →https://doi.org/10.2217/imt.09.82openalex-snapshot

Immune-Based Therapies for Cytomegalovirus Infection

inferredcites →https://doi.org/10.3109/inf.1985.17.issue-2.06openalex-snapshot

Intravenous Foscarnet for the Treatment of Severe Cytomegalovirus Infection in Allograft Recipients

inferredcites →https://doi.org/10.4065/mcp.2011.0309openalex-snapshot

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus

inferredcites →https://doi.org/10.6002/ect.2015.0292openalex-snapshot

Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.

inferredcites →https://doi.org/10.7326/0003-4819-119-10-199311150-00004openalex-snapshot

Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation

inferredcites →https://doi.org/10.7326/0003-4819-123-1-199507010-00002openalex-snapshot

Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients

inferredcites →https://doi.org/10.7326/0003-4819-152-12-201006150-00003openalex-snapshot

Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4118460openalex-extracted

inferred← citeshttps://doi.org/10.2139/ssrn.4772305openalex-extracted

Gastrointestinal Cytomegalovirus Infection in a Transplanted Patient with Negative Serum Viral Load: Case Report

inferred← citeshttps://doi.org/10.1001/jama.2020.3138openalex-snapshot

Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors

inferred← citeshttps://doi.org/10.1001/jama.2021.21510openalex-snapshot

Blurred Vision and Gastrointestinal Bleeding in a Patient With HIV

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.45126openalex-snapshot

Testing for Cytomegalovirus Among Individuals Who Were Immunocompromised, 2018-2022

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.37878openalex-snapshot

Area-Level Social Deprivation and Cytomegalovirus Seropositivity at the Time of Solid Organ Transplant

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.28383openalex-snapshot

A Network for Advancing Prevention and Treatment of Infections Among Immunocompromised Individuals

inferred← citeshttps://doi.org/10.1002/14651858.cd003774.pub5openalex-snapshot

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

inferred← citeshttps://doi.org/10.1002/9781119633884.ch92openalex-snapshot

Transplant Infectious Diseases

inferred← citeshttps://doi.org/10.1002/9781119820260.ch54openalex-snapshot

The Organ Transplant Patient in the Obstetric Critical Care Setting

inferred← citeshttps://doi.org/10.1002/9781683670438.cmm0003.pub2openalex-snapshot

Respiratory Tract Infections

inferred← citeshttps://doi.org/10.1002/9781683670438.mcm0103openalex-snapshot

Human Cytomegalovirus

inferred← citeshttps://doi.org/10.1002/9781683674849.mcm0103openalex-snapshot

Human Cytomegalovirus

inferred← citeshttps://doi.org/10.1002/9783527845088.ch01openalex-snapshot

Letermovir for the Prevention of CMV Infection in Transplant Recipients

inferred← citeshttps://doi.org/10.1002/aid2.13429openalex-snapshot

The role of immunohistochemistry staining and hematoxylin & eosin staining in the diagnosis of cytomegalovirus disease of the gastrointestinal tract

inferred← citeshttps://doi.org/10.1002/cld.1107openalex-snapshot

More Than Meets the Eye?

inferred← citeshttps://doi.org/10.1002/cld.962openalex-snapshot

Spotlight on Impactful Research: Low‐Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate‐Risk Liver Transplantation Recipients

inferred← citeshttps://doi.org/10.1002/cti2.1431openalex-snapshot

Anti‐thymocyte globulin‐mediated immunosenescent alterations of T cells in kidney transplant patients

inferred← citeshttps://doi.org/10.1002/jmv.28507openalex-snapshot

ELISPOT assays with pp65 peptides or whole HCMV antigen are reliable predictors of immune control of HCMV infection in seropositive kidney transplant recipients

inferred← citeshttps://doi.org/10.1002/jmv.29609openalex-snapshot

Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective

inferred← citeshttps://doi.org/10.1002/jmv.70121openalex-snapshot

Epstein‐Barr Virus Infection Presenting With Acute Gastrointestinal Involvement. Report of Two Cases of Epstein‐Barr Virus Colitis in Kidney‐Transplant Recipients and Scoping Review of the Literature

inferred← citeshttps://doi.org/10.1002/jmv.70666openalex-snapshot

Valganciclovir Underdosing Is Associated With Cytomegalovirus DNAemia During Universal Prophylaxis: A Real‐Life Case Control Retrospective Study

inferred← citeshttps://doi.org/10.1002/lt.26045openalex-snapshot

Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients

inferred← citeshttps://doi.org/10.1002/pbc.28101openalex-snapshot

Cytomegalovirus disease in a retinoblastoma cohort: The role of preemptive screening

inferred← citeshttps://doi.org/10.1002/phar.2483openalex-snapshot

Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient

inferred← citeshttps://doi.org/10.1002/phar.2724openalex-snapshot

Temporal shifts in safety and efficacy profile of mycophenolate mofetil 2 g versus 3 g daily early after heart transplantation

inferred← citeshttps://doi.org/10.1002/pro.4915openalex-snapshot

Crystal structure of the tegument protein UL82 (pp71) from human cytomegalovirus

inferred← citeshttps://doi.org/10.1002/rmv.2117openalex-snapshot

Impact of breast milk‐acquired cytomegalovirus infection in premature infants: Pathogenesis, prevention, and clinical consequences?

inferred← citeshttps://doi.org/10.1002/uog.26134openalex-snapshot

Pregnancy management and outcome after uterus transplantation

inferred← citeshttps://doi.org/10.1007/978-1-4939-9544-8_35-1openalex-snapshot

Human Herpesviruses: Cytomegalovirus

inferred← citeshttps://doi.org/10.1007/978-1-4939-9544-8_35-2openalex-snapshot

Human Herpesviruses: Cytomegalovirus

inferred← citeshttps://doi.org/10.1007/978-3-030-01751-4_24-1openalex-snapshot

Cytomegalovirus in Solid Organ Transplant Recipients: Prevention, Diagnosis, and Treatment

inferred← citeshttps://doi.org/10.1007/978-3-030-01751-4_61-1openalex-snapshot

Vascular Composite Allografts (VCA): New Transplants, New Infections

inferred← citeshttps://doi.org/10.1007/978-3-030-01751-4_61-2openalex-snapshot

Vascular Composite Allografts (VCA): New Transplants, New Infections

inferred← citeshttps://doi.org/10.1007/978-3-030-01751-4_65-1openalex-snapshot

Diarrhea in Transplant: Diagnosis and Management

inferred← citeshttps://doi.org/10.1007/978-3-030-01751-4_67-1openalex-snapshot

Transplant Infectious Disease Evaluation of Cytopenias

inferred← citeshttps://doi.org/10.1007/978-3-030-01751-4_68-1openalex-snapshot

Common and Emerging Infections in Pediatric Transplant Recipients

inferred← citeshttps://doi.org/10.1007/978-3-030-01751-4_7-1openalex-snapshot

Antimicrobial Prophylaxis in the Age of Emerging Transplant Infections

inferred← citeshttps://doi.org/10.1007/978-3-030-25869-6_24openalex-snapshot

Cytomegalovirus in Solid Organ Transplant Recipients: Prevention, Diagnosis, and Treatment

inferred← citeshttps://doi.org/10.1007/978-3-030-25869-6_61openalex-snapshot

Vascular Composite Allografts (VCA): New Transplants, New Infections

inferred← citeshttps://doi.org/10.1007/978-3-030-25869-6_67openalex-snapshot

Transplant Infectious Disease Evaluation of Cytopenias

inferred← citeshttps://doi.org/10.1007/978-3-030-25869-6_68openalex-snapshot

Common and Emerging Infections in Pediatric Transplant Recipients

inferred← citeshttps://doi.org/10.1007/978-3-030-25869-6_7openalex-snapshot

Antimicrobial Prophylaxis in the Age of Emerging Transplant Infections

inferred← citeshttps://doi.org/10.1007/978-3-030-44817-2_57-1openalex-snapshot

Electron Microscopy of Viral Infections Affecting the Kidney

inferred← citeshttps://doi.org/10.1007/978-3-030-50629-2_9openalex-snapshot

Common Symptoms in the Adult Solid Organ Transplant Recipient

inferred← citeshttps://doi.org/10.1007/978-3-030-52719-8_101openalex-snapshot

Viral Infections and the Kidney

inferred← citeshttps://doi.org/10.1007/978-3-030-52719-8_67openalex-snapshot

Renal Transplantation: Infectious Complications

inferred← citeshttps://doi.org/10.1007/978-3-031-13569-9_30openalex-snapshot

Successful Management of Complex Primary Cytomegaloviral Disease Utilizing a Standardized Multimodal Approach

inferred← citeshttps://doi.org/10.1007/978-3-031-20999-4_44openalex-snapshot

Post-transplant Infections

inferred← citeshttps://doi.org/10.1007/978-3-031-57369-9_15openalex-snapshot

Cytomegalovirus Infections in Hematopoietic Cell Transplant and Solid Organ Transplant Recipients

inferred← citeshttps://doi.org/10.1007/978-3-031-88290-6_15openalex-snapshot

Pre-transplant Screening and Post-transplant Infection Prevention in Heart Transplant Recipients

inferred← citeshttps://doi.org/10.1007/978-3-031-88290-6_16openalex-snapshot

Managing Infections After Heart Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-031-98076-3_13openalex-snapshot

Gynecologic and Reproductive Health Considerations in the Adult Solid Organ Transplant Recipient

inferred← citeshttps://doi.org/10.1007/978-3-031-98076-3_8openalex-snapshot

Infections in the Adult Solid Organ Transplant Recipient

inferred← citeshttps://doi.org/10.1007/978-3-031-98076-3_9openalex-snapshot

Common Syndromes in the Adult Solid Organ Transplant Recipient

inferred← citeshttps://doi.org/10.1007/978-3-032-07072-2_24openalex-snapshot

Infection After Liver Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-032-12629-0_4openalex-snapshot

Infections After Cardiac Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-032-29861-4_16openalex-snapshot

Special Consideration in Lung Transplantation in Older Patients

inferred← citeshttps://doi.org/10.1007/978-3-642-27843-3_101-1openalex-snapshot

Viral Infections and the Kidney

inferred← citeshttps://doi.org/10.1007/978-3-642-27843-3_67-2openalex-snapshot

Renal Transplantation: Infectious Complications

inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_155-1openalex-snapshot

Therapie von Infektionen bei Tumorpatienten

inferred← citeshttps://doi.org/10.1007/978-981-19-6909-6_16openalex-snapshot

Infectious Complications in Pediatric Renal Transplantation

inferred← citeshttps://doi.org/10.1007/s00134-024-07737-5openalex-snapshot

What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients

inferred← citeshttps://doi.org/10.1007/s00203-023-03623-8openalex-snapshot

Immune-checkpoint expression in antigen-presenting cells (APCs) of cytomegaloviruses infection after transplantation: as a diagnostic biomarker

inferred← citeshttps://doi.org/10.1007/s00277-026-06869-6openalex-snapshot

Comparison of clinical outcomes between early and delayed allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a single-center retrospective study

inferred← citeshttps://doi.org/10.1007/s00408-020-00403-9openalex-snapshot

Infectious Complications in Lung Transplant Recipients

inferred← citeshttps://doi.org/10.1007/s00408-022-00551-0openalex-snapshot

Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction

inferred← citeshttps://doi.org/10.1007/s00431-024-05565-9openalex-snapshot

Association between viral infection and bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1007/s00467-025-06819-wopenalex-snapshot

Performance evaluation of large language models in pediatric nephrology clinical decision support: a comprehensive assessment

inferred← citeshttps://doi.org/10.1007/s00467-026-07378-4openalex-snapshot

Infectious complications in paediatric kidney transplantation: prevention and management

inferred← citeshttps://doi.org/10.1007/s00604-025-07767-wopenalex-snapshot

Creation of an ultra-sensitive and specific molecularly imprinted polymer sensor with ZnO nanoparticle assistance for valganciclovir detection

inferred← citeshttps://doi.org/10.1007/s10096-019-03744-3openalex-snapshot

Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus–positive kidney transplant recipient

inferred← citeshttps://doi.org/10.1007/s10157-024-02578-4openalex-snapshot

Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study

inferred← citeshttps://doi.org/10.1007/s10238-024-01330-2openalex-snapshot

Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences

inferred← citeshttps://doi.org/10.1007/s10238-024-01358-4openalex-snapshot

Correction to: Letermovir prophylaxis for cytomegalovirus in lung‑transplant recipients: a comprehensive study with literature review of off‑label use and real‑world experiences

inferred← citeshttps://doi.org/10.1007/s11255-025-04399-0openalex-snapshot

Secular trends in cytomegalovirus (CMV) risk and outcomes: results from a 10-year longitudinal cohort study in adult kidney transplant recipients

inferred← citeshttps://doi.org/10.1007/s11560-024-00787-2openalex-snapshot

48/w mit Durchfall und nachlassender Diurese, Z. n. Nierentransplantation vor 11 Monaten

inferred← citeshttps://doi.org/10.1007/s11908-019-0699-0openalex-snapshot

CMV Prevention and Treatment in Transplantation: What’s New in 2019

inferred← citeshttps://doi.org/10.1007/s11936-021-00933-2openalex-snapshot

Post-transplant Management in Heart Transplant Recipients: New Drugs and Prophylactic Strategies

inferred← citeshttps://doi.org/10.1007/s12072-023-10629-3openalex-snapshot

Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation

inferred← citeshttps://doi.org/10.1007/s12185-025-04124-8openalex-snapshot

Comparison of quantitative PCR values and antigenemia for CMV monitoring in hematopoietic cell transplant recipients

inferred← citeshttps://doi.org/10.1007/s12325-025-03210-xopenalex-snapshot

Patient Number and Treatment Patterns in Cytomegalovirus Viremia and Disease Following Solid Organ and Hematopoietic Stem Cell Transplantation in Germany: Results of a Delphi Consensus Study

inferred← citeshttps://doi.org/10.1007/s13665-020-00245-zopenalex-snapshot

Donor-Derived Disease Transmission in Lung Transplantation

inferred← citeshttps://doi.org/10.1007/s13665-020-00246-yopenalex-snapshot

Human Cytomegalovirus Prophylaxis and Treatment in Lung Transplantation in the Current Era

inferred← citeshttps://doi.org/10.1007/s15010-024-02441-4openalex-snapshot

Prophylactic vs preemptive strategy for the prevention of CMV disease in solid organ transplant recipients: systematic review and meta-analysis of randomized controlled trials

inferred← citeshttps://doi.org/10.1007/s40121-021-00452-4openalex-snapshot

Cytomegalovirus Infection and the Implications of Drug-Resistant Mutations in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Retrospective Study from a Tertiary Hospital in China

inferred← citeshttps://doi.org/10.1007/s40121-025-01159-6openalex-snapshot

Tackling CMV in Transplant Recipients: Past, Present, and Future

inferred← citeshttps://doi.org/10.1007/s40123-024-00968-1openalex-snapshot

Incidence of Cytomegalovirus Infection After Repeat Keratoplasty and Associated Rate of Graft Failure

inferred← citeshttps://doi.org/10.1007/s40262-021-01034-wopenalex-snapshot

Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients

inferred← citeshttps://doi.org/10.1007/s40262-024-01362-7openalex-snapshot

Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning

inferred← citeshttps://doi.org/10.1007/s40262-025-01526-zopenalex-snapshot

Pharmacokinetic/Pharmacodynamic Modelling and Monte Carlo Simulations to Predict Cytomegalovirus Viral Load in Pediatric Transplant Recipients Treated with (val)Ganciclovir

inferred← citeshttps://doi.org/10.1007/s40272-022-00512-3openalex-snapshot

Immunosuppression Regimens for Intestinal Transplantation in Children

inferred← citeshttps://doi.org/10.1007/s40472-020-00268-0openalex-snapshot

Management of Antimicrobial Agents in Abdominal Organ Transplant Patients in Intensive Care Unit

inferred← citeshttps://doi.org/10.1007/s40472-021-00320-7openalex-snapshot

A Comprehensive Review of Infections in Older Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1007/s40472-022-00385-yopenalex-snapshot

Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”

inferred← citeshttps://doi.org/10.1007/s40506-025-00288-3openalex-snapshot

Refractory CMV: A Review of Current Approaches

inferred← citeshttps://doi.org/10.1007/s40620-022-01455-1openalex-snapshot

CMV retinitis in a kidney transplant recipient

inferred← citeshttps://doi.org/10.1007/s41669-026-00679-2openalex-snapshot

Budget Impact of Prophylactic Letermovir to Prevent Cytomegalovirus Disease in High-Risk Adult Kidney Transplant Recipients

inferred← citeshttps://doi.org/10.1016/b978-0-08-102723-3.00259-6openalex-snapshot

Opportunistic Bacterial, Fungal and Viral Infections in Lung Transplantation

inferred← citeshttps://doi.org/10.1016/b978-0-12-814515-9.00134-xopenalex-snapshot

Treatment and Prevention of Herpesvirus Infections in the Immunocompromised Host

inferred← citeshttps://doi.org/10.1016/b978-0-12-814582-1.00013-9openalex-snapshot

Cytomegalovirus

inferred← citeshttps://doi.org/10.1016/b978-0-12-818006-8.00008-6openalex-snapshot

Transplantation

inferred← citeshttps://doi.org/10.1016/b978-0-12-818619-0.00110-6openalex-snapshot

Viral monitoring in immunocompromised hosts

inferred← citeshttps://doi.org/10.1016/b978-0-12-818731-9.00175-0openalex-snapshot

Treatment of Secondary Immunodeficiencies

inferred← citeshttps://doi.org/10.1016/b978-0-323-75608-2.00036-7openalex-snapshot

Pneumonia in the Immunocompromised Host

inferred← citeshttps://doi.org/10.1016/b978-0-323-75608-2.00095-1openalex-snapshot

Infections in Solid Organ Transplant Recipients

inferred← citeshttps://doi.org/10.1016/b978-0-323-82763-8.00072-8openalex-snapshot

Infections in Pediatric Heart Transplantation

inferred← citeshttps://doi.org/10.1016/b978-0-323-82763-8.00073-xopenalex-snapshot

Infections in Pediatric Lung Transplantation

inferred← citeshttps://doi.org/10.1016/b978-0-323-95061-9.00051-5openalex-snapshot

Management and prophylaxis of infections in primary immunodeficiency

inferred← citeshttps://doi.org/10.1016/b978-0-443-11611-7.00118-3openalex-snapshot

Lung transplantation

inferred← citeshttps://doi.org/10.1016/b978-0-443-26710-9.00024-9openalex-snapshot

Hepatitis through non-A–E viruses

inferred← citeshttps://doi.org/10.1016/b978-0-443-26711-6.00037-8openalex-snapshot

Liver in systemic diseases—Part 2

inferred← citeshttps://doi.org/10.1016/bs.seda.2025.08.010openalex-snapshot

Adverse effects of clinically relevant antiviral drugs

inferred← citeshttps://doi.org/10.1016/j.ajog.2023.04.022openalex-snapshot

Society for Maternal-Fetal Medicine Consult Series #66: Prepregnancy evaluation and pregnancy management of patients with solid organ transplants

inferred← citeshttps://doi.org/10.1016/j.ajt.2023.10.007openalex-snapshot

Risk of cytomegalovirus infection and subsequent allograft failure after pancreas transplantation

inferred← citeshttps://doi.org/10.1016/j.ajt.2024.05.019openalex-snapshot

Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients

inferred← citeshttps://doi.org/10.1016/j.ajt.2025.07.2471openalex-snapshot

Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis

inferred← citeshttps://doi.org/10.1016/j.ajt.2026.05.1503openalex-snapshot

Prevalence and Hospitalization Burden of Cytomegalovirus Infection in Solid Organ Transplant Recipients in the United States

inferred← citeshttps://doi.org/10.1016/j.ajt.2026.07.018openalex-snapshot

Cytomegalovirus infection after lung transplant: Incidence, risk factors, and management in a multicenter cohort

inferred← citeshttps://doi.org/10.1016/j.antiviral.2023.105623openalex-snapshot

Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients

inferred← citeshttps://doi.org/10.1016/j.aohep.2025.101899openalex-snapshot

Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantation

inferred← citeshttps://doi.org/10.1016/j.athplu.2022.03.003openalex-snapshot

Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events

inferred← citeshttps://doi.org/10.1016/j.bpobgyn.2026.102748openalex-snapshot

Preventing congenital cytomegalovirus infection in transplant recipients; a focus on uterine transplantation

inferred← citeshttps://doi.org/10.1016/j.carpath.2024.107701openalex-snapshot

Cause of death for heart transplant patients, an autopsy study

inferred← citeshttps://doi.org/10.1016/j.ccc.2023.05.004openalex-snapshot

Heart Transplantation—Postoperative Considerations

inferred← citeshttps://doi.org/10.1016/j.ccm.2022.10.012openalex-snapshot

Opportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial

inferred← citeshttps://doi.org/10.1016/j.cellimm.2021.104455openalex-snapshot

Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation

inferred← citeshttps://doi.org/10.1016/j.chest.2024.05.033openalex-snapshot

Diseases Involving the Lung Peribronchovascular Region

inferred← citeshttps://doi.org/10.1016/j.cjca.2019.12.025openalex-snapshot

Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care

inferred← citeshttps://doi.org/10.1016/j.cld.2022.08.006openalex-snapshot

Evaluation of an Abnormal Liver Panel After Liver Transplantation

inferred← citeshttps://doi.org/10.1016/j.clim.2023.109782openalex-snapshot

Intravenous immunoglobulin in kidney transplantation: Mechanisms of action, clinical applications, adverse effects, and hyperimmune globulin

inferred← citeshttps://doi.org/10.1016/j.clinmicnews.2021.08.003openalex-snapshot

Diagnosis and Monitoring of Viral Infections in the Transplant Population

inferred← citeshttps://doi.org/10.1016/j.cmi.2022.05.034openalex-snapshot

Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression

inferred← citeshttps://doi.org/10.1016/j.cmi.2022.07.001openalex-snapshot

Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium

inferred← citeshttps://doi.org/10.1016/j.cmi.2023.03.020openalex-snapshot

Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients

inferred← citeshttps://doi.org/10.1016/j.crmeth.2026.101458openalex-snapshot

Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows

inferred← citeshttps://doi.org/10.1016/j.diagmicrobio.2024.116301openalex-snapshot

Evaluation of Alinity m CMV assay performance for detecting CMV in plasma, cerebrospinal fluid, and bronchoalveolar lavage specimens

inferred← citeshttps://doi.org/10.1016/j.eimc.2020.01.021openalex-snapshot

Prevention and therapy of viral infections in patients with solid organ transplantation

inferred← citeshttps://doi.org/10.1016/j.eimc.2025.503078openalex-snapshot

CMV-specific cellular immunity in solid organ transplantation: Challenges and opportunities for clinical implementation

inferred← citeshttps://doi.org/10.1016/j.eimce.2020.01.019openalex-snapshot

Prevention and therapy of viral infections in patients with solid organ transplantation

inferred← citeshttps://doi.org/10.1016/j.eimce.2026.503078openalex-snapshot

CMV-specific cellular immunity in solid organ transplantation: Challenges and opportunities for clinical implementation

inferred← citeshttps://doi.org/10.1016/j.ekir.2021.11.022openalex-snapshot

One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial

inferred← citeshttps://doi.org/10.1016/j.gtc.2021.02.013openalex-snapshot

Infectious Gastroenteritis in Transplant Patients

inferred← citeshttps://doi.org/10.1016/j.gtc.2026.01.004openalex-snapshot

Clinical Follow-Up After Intestinal Transplantation

inferred← citeshttps://doi.org/10.1016/j.healun.2021.12.005openalex-snapshot

Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis

inferred← citeshttps://doi.org/10.1016/j.healun.2022.09.023openalex-snapshot

WITHDRAWN: Executive Summary - The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients

inferred← citeshttps://doi.org/10.1016/j.healun.2022.10.015openalex-snapshot

The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients

inferred← citeshttps://doi.org/10.1016/j.healun.2023.10.005openalex-snapshot

Cytomegalovirus infection is associated with impaired myocardial flow reserve after heart transplantation

inferred← citeshttps://doi.org/10.1016/j.healun.2023.11.017openalex-snapshot

Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors

inferred← citeshttps://doi.org/10.1016/j.healun.2024.11.026openalex-snapshot

Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study

inferred← citeshttps://doi.org/10.1016/j.healun.2025.09.017openalex-snapshot

Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement

inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e16792openalex-snapshot

Interferon-gamma FlowSpot assay for the measurement of the T-cell response to cytomegalovirus

inferred← citeshttps://doi.org/10.1016/j.heliyon.2025.e43904openalex-snapshot

CMV resistant to ganciclovir and maribavir in a heart-transplanted Patient: A case report

inferred← citeshttps://doi.org/10.1016/j.idc.2019.05.008openalex-snapshot

Opportunistic Infections in Transplant Patients

inferred← citeshttps://doi.org/10.1016/j.idc.2020.02.002openalex-snapshot

Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis

inferred← citeshttps://doi.org/10.1016/j.idc.2021.11.004openalex-snapshot

Antiviral Therapeutics in Pediatric Transplant Recipients

inferred← citeshttps://doi.org/10.1016/j.idc.2023.03.004openalex-snapshot

Immunization of Solid Organ Transplant Candidates and Recipients

inferred← citeshttps://doi.org/10.1016/j.idc.2023.04.003openalex-snapshot

Organ Donors with Human Immunodeficiency Virus and Hepatitis C Virus

inferred← citeshttps://doi.org/10.1016/j.idc.2023.04.005openalex-snapshot

Opportunities for Antimicrobial Stewardship Interventions Among Solid Organ Transplant Recipients

inferred← citeshttps://doi.org/10.1016/j.idc.2023.05.002openalex-snapshot

Minimizing the Risk of Donor-Derived Events and Maximizing Organ Utilization Through Education and Policy Development

inferred← citeshttps://doi.org/10.1016/j.idc.2023.06.002openalex-snapshot

Update on Epidemiology and Outcomes of Infection in Pediatric Organ Transplant Recipients

inferred← citeshttps://doi.org/10.1016/j.idc.2023.10.001openalex-snapshot

Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation

inferred← citeshttps://doi.org/10.1016/j.idc.2023.12.001openalex-snapshot

Opportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial

inferred← citeshttps://doi.org/10.1016/j.idcr.2020.e00932openalex-snapshot

Cytomegalovirus pancreatitis in an immunocompetent patient

inferred← citeshttps://doi.org/10.1016/j.ijid.2023.04.387openalex-snapshot

Risk factors for late-onset Pneumocystis jirovecii pneumonia in liver transplant recipients

inferred← citeshttps://doi.org/10.1016/j.ijid.2025.108073openalex-snapshot

Prophylaxis followed by preemptive approach versus prophylaxis to prevent CMV infection in CMV-seropositive kidney transplant recipients receiving anti-thymocyte globulin induction therapy

inferred← citeshttps://doi.org/10.1016/j.ijid.2025.108311openalex-snapshot

Logical versus absolute lymphocyte count–guided preemptive therapy for cytomegalovirus prevention in kidney transplant recipients: a randomized controlled trial

inferred← citeshttps://doi.org/10.1016/j.jccase.2023.04.013openalex-snapshot

Cytomegalovirus infection in heart transplant patient presenting as appendicitis

inferred← citeshttps://doi.org/10.1016/j.jceh.2024.101363openalex-snapshot

Rejection in Liver Transplantation Recipients

inferred← citeshttps://doi.org/10.1016/j.jcv.2019.104211openalex-snapshot

CMV infection management in transplant patients in Italy

inferred← citeshttps://doi.org/10.1016/j.jcv.2022.105122openalex-snapshot

Evaluation of the sample-to-result, random access NeuMoDx platform for viral load testing of Cytomegalovirus and Epstein Barr virus in clinical specimens

inferred← citeshttps://doi.org/10.1016/j.jcv.2022.105243openalex-snapshot

A Prospective Study of Plasma and Bronchoalveolar Lavage Fluid CMV DNA Load Quantification for the Diagnosis and Outcome of CMV Pneumonitis in Immunocompromised Hosts

inferred← citeshttps://doi.org/10.1016/j.jcv.2023.105467openalex-snapshot

Performance evaluation of the Aptima CMV quant assay using plasma and non-plasma samples

inferred← citeshttps://doi.org/10.1016/j.jcv.2023.105550openalex-snapshot

Evaluation of the fully automated LIAISON®XL chemiluminescence analyzer for QuantiFERON®-CMV testing in transplant recipients

inferred← citeshttps://doi.org/10.1016/j.jcv.2023.105637openalex-snapshot

Evaluation of an automated real-time transcription-mediated amplification (TMA) assay for detection and quantification of cytomegalovirus DNA in different clinical specimens

inferred← citeshttps://doi.org/10.1016/j.jcvp.2026.100259openalex-snapshot

Streamlining viral surveillance in transplant patients with the Alinity m Platform

inferred← citeshttps://doi.org/10.1016/j.jcyt.2026.102909openalex-snapshot

Impact of CMV infection on pediatric allogeneic HSCT outcomes in a region of high CMV seroprevalence: a non-TBI cohort study

inferred← citeshttps://doi.org/10.1016/j.jfma.2024.05.009openalex-snapshot

Prevention and management of cytomegalovirus infection and disease in kidney transplant: A consensus statement of the Transplantation Society of Taiwan

inferred← citeshttps://doi.org/10.1016/j.jhlto.2023.100047openalex-snapshot

Cytomegalovirus infection in heart transplant recipients: Epidemiology, risk factors, and long-term outcomes from a major transplant center in the United States

inferred← citeshttps://doi.org/10.1016/j.jhlto.2024.100063openalex-snapshot

A call for cytomegalovirus stewardship initiatives in cardiothoracic transplant

inferred← citeshttps://doi.org/10.1016/j.jhlto.2024.100113openalex-snapshot

Evaluating longitudinal cytomegalovirus-specific humoral immune responses and association with DNAemia risk in seropositive lung transplant recipients

inferred← citeshttps://doi.org/10.1016/j.jhlto.2025.100409openalex-snapshot

Pretransplant screening for infections in lung and heart transplant candidates

inferred← citeshttps://doi.org/10.1016/j.jhlto.2025.100449openalex-snapshot

Cytomegalovirus infections in thoracic organ transplant recipients: Updates on prevention, treatment, and immune monitoring

inferred← citeshttps://doi.org/10.1016/j.jiac.2022.07.004openalex-snapshot

Factors associated with cytomegalovirus antigenemia in patients with rheumatic disease: A retrospective study

inferred← citeshttps://doi.org/10.1016/j.jim.2023.113577openalex-snapshot

Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies

inferred← citeshttps://doi.org/10.1016/j.jiph.2025.102845openalex-snapshot

RPA-CRISPR/Cas12a detection based on HCMV-UL123 gene: A way with higher detection rate than clinical detection methods

inferred← citeshttps://doi.org/10.1016/j.jmii.2025.04.002openalex-snapshot

Risk of cytomegalovirus infection in solid organ transplant recipients: A population-based cross-sectional study

inferred← citeshttps://doi.org/10.1016/j.jmoldx.2026.01.004openalex-snapshot

Viral Load Pre-emptive Monitoring in the Post-Transplant Immunocompromised Population

inferred← citeshttps://doi.org/10.1016/j.jtct.2021.05.001openalex-snapshot

American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation

inferred← citeshttps://doi.org/10.1016/j.jviromet.2024.115068openalex-snapshot

Evaluation and comparison of three high throughput assays (Alinity m CMV, Aptima CMV Quant and cobas CMV) for quantifying CMV DNA in plasma samples

inferred← citeshttps://doi.org/10.1016/j.liver.2025.100299openalex-snapshot

The current status of CMV prophylaxis and treatment in liver transplant recipients: A single center study

inferred← citeshttps://doi.org/10.1016/j.med.2022.05.012openalex-snapshot

Infecciones en el paciente inmunocomprometido (II). Pacientes con trasplante de órgano sólido

inferred← citeshttps://doi.org/10.1016/j.nurpra.2024.105066openalex-snapshot

Improving Vaccine Uptake Among Solid Organ Transplant Candidates

inferred← citeshttps://doi.org/10.1016/j.pharmthera.2022.108121openalex-snapshot

Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences

inferred← citeshttps://doi.org/10.1016/j.preteyeres.2020.100876openalex-snapshot

Corneal xenotransplantation: Where are we standing?

inferred← citeshttps://doi.org/10.1016/j.ram.2025.10.006openalex-snapshot

Estrategias para el diagnóstico y monitoreo de citomegalovirus en pacientes trasplantados

inferred← citeshttps://doi.org/10.1016/j.resinv.2025.02.002openalex-snapshot

Key predictors of long-term survival after lung transplantation in Japan

inferred← citeshttps://doi.org/10.1016/j.semarthrit.2024.152396openalex-snapshot

Qualitative evaluation of connective tissue disease with cytomegalovirus infection: A meta-analysis of case reports

inferred← citeshttps://doi.org/10.1016/j.thorsurg.2021.12.002openalex-snapshot

Infectious Complications in Lung Transplant Recipients

inferred← citeshttps://doi.org/10.1016/j.tim.2022.12.003openalex-snapshot

Novel monoclonal antibody-based therapies: implications for the treatment and prevention of HCMV disease

showing the first 200 of 754

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.